Increased serum TWEAK levels in Psoriatic arthritis: Relationship with disease activity and matrix metalloproteinase-3 serum levels

Cytokine

Volumn 53, Issue 3, 2011, Pages 289-291

  Xia, Liping ^a   Shen, Hui ^a   Xiao, Weiguo ^a   Lu, Jing ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Psoriatic arthritis; Tumor necrosis factor related weak inducer of apoptosis

Indexed keywords

INTERLEUKIN 15; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMELYSIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; SCORING SYSTEM;

ADULT; AGED; ARTHRITIS, PSORIATIC; CHEMOKINE CCL2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-15; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; OSTEOARTHRITIS; TUMOR NECROSIS FACTORS;

EID: 79251620726     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.12.003     Document Type: Article

References (9)

1. Wiley S.R., Winkles J.A. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003, 14(3-4):241-249.
2. Kamijo S., Nakajima A., Kamata K., Kurosawa H., Yagita H., Okumura K. Involvement of TWEAK/Fn14 interaction in the synovial inflammation of RA. Rheumatology (Oxford) 2008 Apr, 47(4):442-450.
3. Kamata K., Kamijo S., Nakajima A., Koyanagi A., Kurosawa H., Yagita H., et al. Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol 2006, 177(9):6433-6439.
4. van Kuijk A.W., Wijbrandts C.A., Vinkenoog M., Zheng T.S., Reedquist K.A., Tak P.P. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Ann Rheum Dis 2010 Jan, 69(1):301-304.
5. Gladman D.D., Antoni C., Mease P., Clegg D.O., Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005, 64(Suppl. 2ii):14-17.
6. van Kuijk A.W., Reinders-Blankert P., Smeets T.J., Dijkmans B.A., Tak P.P. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006 Dec, 65(12):1551-1557.
7. McLInnes I.B. Cytokine targeting in psoriasis and psoriatic arthritis: beyond TNFalpha. Ernst Schering Res Found Workshop 2006, 56:29-44.
8. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006 Aug, 54(8):2665-2673.
9. Chicheportiche Y., Chicheportiche R., Sizing I., Thompson J., Benjamin C.B., Ambrose C., et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002, 4(2):126-133.